Morepen Laboratories' Q3 FY 2025-26 Quarterly Results
- 11 Feb 2026
Result Summary
- Morepen Laboratories Ltd reported a 17.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 6.5%.
- Its expenses for the quarter were up by 14.2% QoQ and 7.0% YoY.
- The net profit decreased 33.0% QoQ and increased 3.0% YoY.
- The earnings per share (EPS) of Morepen Laboratories Ltd stood at 0.5 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 487.97 | 416.21 | 458.12 | 17.2% | 6.5% |
Total Expenses | 452.54 | 396.34 | 422.91 | 14.2% | 7.0% |
Profit Before Tax | 35.42 | 45.69 | 35.21 | -22.5% | 0.6% |
Tax | 7.93 | 4.65 | 8.52 | 70.5% | -6.9% |
Profit After Tax | 27.50 | 41.04 | 26.69 | -33.0% | 3.0% |
Earnings Per Share | 0.50 | 0.75 | 0.49 | -33.3% | 2.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Morepen Laboratories Ltd is a prominent player in the pharmaceutical industry. The company is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), formulations, and diagnostics. Morepen Laboratories has a diversified portfolio, including over-the-counter products, and has been known for its high-quality standards in drug manufacturing. The company operates in a highly competitive sector, with a focus on both domestic and international markets. Recent developments have seen Morepen Laboratories expanding its production capabilities and enhancing its research and development efforts to strengthen its product offerings.
Revenue
In Q3FY26, Morepen Laboratories Ltd reported a total income of ₹487.97 crores, marking a significant quarter-over-quarter (QoQ) increase of 17.2% from ₹416.21 crores in Q2FY26. Compared to the same quarter in the previous year (Q3FY25), where the total income was ₹458.12 crores, the company achieved a year-over-year (YoY) growth of 6.5%. This growth trajectory indicates a robust revenue performance for the quarter. The company's ability to consistently increase its total income highlights its strong market presence and effective sales strategies in its industry.
Profitability
Morepen Laboratories' profitability metrics for Q3FY26 reveal several key points. The profit before tax (PBT) for the quarter was ₹35.42 crores, representing a QoQ decrease of 22.5% from ₹45.69 crores in Q2FY26, but a slight YoY increase of 0.6% from ₹35.21 crores in Q3FY25. The tax expense for Q3FY26 was ₹7.93 crores, showing a significant QoQ increase of 70.5% compared to Q2FY26 and a YoY decrease of 6.9% from Q3FY25. The profit after tax (PAT) stood at ₹27.50 crores, which is a QoQ decline of 33.0% from ₹41.04 crores in Q2FY26, but a YoY increase of 3.0% from ₹26.69 crores in Q3FY25. Earnings per share (EPS) for Q3FY26 was ₹0.50, reflecting a decrease from ₹0.75 in Q2FY26 and a slight increase from ₹0.49 in Q3FY25, with QoQ and YoY changes of -33.3% and 2.0% respectively.
Operating Metrics
In terms of operating metrics, the total expenses for Q3FY26 were ₹452.54 crores, reflecting a QoQ increase of 14.2% from ₹396.34 crores in Q2FY26, and a YoY increase of 7.0% from ₹422.91 crores in Q3FY25. This rise in expenses is significant and impacts the overall profitability of the company. The financial data highlights the balance between revenue growth and expense management, which is crucial for sustaining profitability in the competitive pharmaceutical industry. The company's operational efficiency can be further analyzed by looking at the changes in these key metrics over the observed periods, which provide insights into its cost management strategies and operational scale.